{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039759","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.205273+00:00","generated_at":"2026-06-12T01:44:19.431190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Personalis Q2 revenue $16.7M (-8% YoY); net loss $24.0M; tightens FY guidance to $70-72M","bullets":["Total revenue $16.7M vs $18.2M in Q2 2022, an 8% decrease; pharma/enterprise revenue $13.7M, down 3%.","Net loss $24.0M ($0.50 EPS) vs $24.8M loss in Q2 2022; cash and investments $137.2M as of June 30.","FY 2023 revenue guidance tightened to $70M-$72M; net loss expected ~$103M, cash usage ~$70M.","VA MVP exercised first of four one-year renewal options; second patent lawsuit filed against Foresight Diagnostics.","Announced collaboration with National Cancer Center Hospital East and Ono Pharmaceutical for rectal cancer biomarker analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039759","json":"https://secwatch.observer/filing/0000950170-23-039759.json","markdown":"https://secwatch.observer/filing/0000950170-23-039759.md","text":"https://secwatch.observer/filing/0000950170-23-039759.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023039759/0000950170-23-039759-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023039759/psnl-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:44:19.431190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a8c30aae24a1395d331e67d02efb363070b8d0ab","claim":"Personalis, Inc. reported second quarter ended June 30, 2023 results: revenue $16.7 million, net income $24.0 million, EPS $0.50.","evidence_excerpt":"evidence, we are paving the way for our successful entry into the clinical diagnostics market.” Second Quarter Financial Highlights • Reported total company revenue of $16.7 million for the second quarter of 2023, representing an 8% decrease compared with $18.2 million for the second quarter of 2022 o Revenue from pharma tests, enterprise sales, and other","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023039759/0000950170-23-039759-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$16.7 million"},{"label":"Net income","value":"$24.0 million"},{"label":"EPS","value":"$0.50"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}